Saturday Dec 14
Puma Biotechnology Updates on Data from I-SPY 2 Trial
In a release, the Company noted that the I-SPY 2 Trial is a randomized Phase II clinical trial for women with newly diagnosed Stage 2 or higher breast cancer that addresses whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy.
Fri Dec 13, 2013
Merrimack Announces Encouraging Clinical Data From Expanded Phase 1...
Merrimack Pharmaceuticals, Inc. today announced Phase 1 clinical trial results for MM-302, a novel HER2-targeted liposomal doxorubicin for the treatment of advanced HER2-positive breast cancer.
Medical News Today
Highly effective treatment option identified for patients with HER2-positive breast cancer
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer , regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented at the ... (more)
Medical News Today
Identifying breast cancer patients most likely to benefit from trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Wed Dec 11, 2013
ImmunoGen's CEO Presents at Oppenheimer 24th Annual Healthcare Conference
We continue with our presentation. The next company to present is going to be ImmunoGen and it's my pleasure to introduce the President and CEO of ImmunoGen, Mr. Daniel Junius.
Data on Monoclonal Antibodies Detailed by Researchers at University Health Network
Active targeting of nanoparticles has been exploited as a means to increase the therapeutic efficacy of NP-based drugs by promoting their delivery to cellular sites of action."
Researchers to present event-free and overall survival results from NeoALTTO trial
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Use of Roche's Herceptin Among HER2+ Gastric Cancer Patients May ...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists in China are embracing Roche's Herceptin as the targeted therapy for treating HER2+ gastric cancer in the first-line setting.
Wed Dec 04, 2013
Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL
Puma Biotechnology, Inc. , a development stage biopharmaceutical company, today announced top line results from the Phase II clinical trial of Puma's investigational drug PB272 for the neoadjuvant treatment of breast cancer .
Nontoxic Hydrogel Improves Delivery of Breast Cancer Drug
The treatment of breast cancer usually involves surgery followed by a course of chemotherapy, radiotherapy, or hormone therapy designed to reduce the risk of recurrence.
Fri Nov 29, 2013
The Family Badge
News From The Office of The Inspector General
Medicare Contractors Nationwide Overpaid Millions to Providers for Full Vials of Herceptin http://go.usa.gov/WHT4 This report summarizes the results of our individual reviews related to incorrect billings for full vials of Herceptin and evaluates the effectiveness of the Herceptin-specific edit that was implemented after our audit period.
Wed Nov 27, 2013
Current and emerging targeted therapies for metastatic breast cancer
The success of endocrine therapies for hormone receptor-positive breast cancer and trastuzumab and lapatinib for targeting human epidermal growth factor receptor 2 -positive tumors has paved the way for the clinical development of several other metastatic breast cancer -targeted therapies.
Why Adjuvant Trastuzumab Led to Better Outcomes in Women with High-Risk HER-2-Positive Breast Cancer
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Tue Nov 26, 2013
Regulatory nod for Biocon to market cancer drug - Indiatalkies.com
Bangalore, Nov 26: Leading biotech firm Biocon Ltd got regulatory approval to market a drug it developed jointly with the US-based pharma major Mylan to treat breast cancer.
Mon Nov 25, 2013
Mylan-Biocon Receive First Indian Biosimilar Regulatory Approval for Herceptin
Mylan Inc. has announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India.
Thu Nov 21, 2013
Wed Nov 20, 2013
Findings from Fudan University Yields New Data on Cancer Vaccines
Although dendritic cell vaccines have been extensively applied in clinical trials for cancer treatment, the vaccination efficacy is still limited, mostly because DC vaccines are not sufficient to break tumor-associated antigen-specific self-immune tolerance in cancer patients."
Tue Nov 19, 2013
Customer Interaction Solutions
ImmunoGen, Inc. Announces Approval of Roche's Kadcyla in the European Union
This event triggers a $5 million milestone payment to ImmunoGen. Kadcyla has been approved for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination.
Mon Nov 18, 2013
Study explains why drug may help more cancer patients
Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications may somehow still benefit from treatment with the medication.